# Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Knee Replacement Surgery

> **NCT00917254** · PHASE2,PHASE3 · COMPLETED · sponsor: **Astellas Pharma Inc** · enrollment: 369 (actual)

## Conditions studied

- Venous Thromboembolism

## Interventions

- **DRUG:** YM150
- **DRUG:** Placebo
- **DRUG:** Enoxaparin

## Key facts

- **NCT ID:** NCT00917254
- **Lead sponsor:** Astellas Pharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-05
- **Primary completion:** 2010-01
- **Final completion:** 2010-01
- **Target enrollment:** 369 (ACTUAL)
- **Last updated:** 2010-06-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00917254

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00917254, "Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Knee Replacement Surgery". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00917254. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*